MBL2 polymorphism and risk of severe infections in multiple myeloma patients receiving high-dose melphalan and autologous stem cell transplantation

Bone Marrow Transplantation

Volumn 38, Issue 8, 2006, Pages 555-560

  Molle I ^a   Peterslund, N A ^a   Thiel, S ^b   Steffensen, R ^c  

^a AARHUS UNIVERSITY HOSPITAL   (Denmark)

^b AARHUS UNIVERSITY   (Denmark)

^c AALBORG UNIVERSITY HOSPITAL   (Denmark)

Author keywords

Autologous stem cell transplantation; Infections; Mannan binding lectin; Multiple myeloma

Indexed keywords

AMPHOTERICIN B; CEFTAZIDIME; CYCLOPHOSPHAMIDE; DEXAMETHASONE; DOXORUBICIN; MANNAN BINDING LECTIN; MELPHALAN; VANCOMYCIN; VINCRISTINE;

ADULT; AGED; ALLELE; ARTICLE; AUTOLOGOUS STEM CELL TRANSPLANTATION; COMPLEMENT ACTIVATION; CONFIDENCE INTERVAL; CONTROLLED STUDY; DISEASE SEVERITY; DRUG MEGADOSE; FEMALE; GENETIC POLYMORPHISM; HOMOZYGOSITY; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; INFECTION RISK; INNATE IMMUNITY; MAJOR CLINICAL STUDY; MALE; MULTIPLE MYELOMA; MULTIVARIATE ANALYSIS; PRIORITY JOURNAL; PROTEIN POLYMORPHISM; RISK ASSESSMENT; RISK REDUCTION; SEPTICEMIA; WILD TYPE;

ADULT; AGED; FEMALE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; IMMUNITY; INFECTION; MALE; MANNOSE-BINDING LECTIN; MELPHALAN; MIDDLE AGED; MULTIPLE MYELOMA; POLYMORPHISM, GENETIC; RETROSPECTIVE STUDIES; RISK; TRANSPLANTATION, AUTOLOGOUS;

EID: 33749439349     PISSN: 02683369     EISSN: 14765365     Source Type: Journal    
DOI: 10.1038/sj.bmt.1705466     Document Type: Article

References (29)

1. Papadea C, Reimer CB, Check IJ. IgG subclass distribution in patients with multiple myeloma or with monoclonal gammopathy of undetermined significance. Ann Clin Lab Sci 1989; 19: 27-37.
2. Jacobson DR, Zolla-Pazner S. Immunosuppression and infection in multiple myeloma. Semin Oncol 1986; 13: 282-290.
3. Mozaffari F, Hansson L, Kiaii S, Ju X, Rossmann ED, Rabbani H et al. Signalling molecules and cytokine production in T cells of multiple myeloma-increased abnormalities with advancing stage. Br J Haematol 2004; 124: 315-324.
4. Cook G, Clark RE, Morris TC, Robertson M, Lucie NP, Anderson S et al. A randomized study (WOS MM1) comparing the oral regime Z-Dex (idarubicin and dexamethasone) with vincristine, adriamycin and dexamethasone as induction therapy for newly diagnosed patients with multiple myeloma. Br J Haematol 2004; 126: 792-798.
5. Oken MM, Harrington DP, Abramson N, Kyle RA, Knospe W, Glick JH. Comparison of melphalan and prednisone with vincristine, carmustine, melphalan, cyclophosphamide, and prednisone in the treatment of multiple myeloma: Results of Eastern Cooperative Oncology Group Study E2479. Cancer 1997; 79: 1561-1567.
6. Augustson BM, Begum G, Dunn JA, Barth NJ, Davies F, Morgan G et al. Early mortality after diagnosis of Multiple Myeloma: Analysis of patients entered onto the United Kingdom Medical Research Council Trials between 1980 and 2002-Medical Research Council Adult Leukaemia Working Party. J Clin Oncol 2005; 23: 9219-9226.
7. Lenhoff S, Hjorth M, Holmberg E, Turesson I, Westin J, Nielsen JL et al. Impact on survival of high-dose therapy with autologous stem cell support in patients younger than 60 years with newly diagnosed multiple myeloma: A population-based study. Nordic Myeloma Study Group. Blood 2000; 95: 7-11.
8. Child JA, Morgan GJ, Davies FE, Owen RG, Bell SE, Hawkins K et al. High-dose chemotherapy with hematopoietic stem-cell rescue for multiple myeloma. N Engl J Med 2003; 348: 1875-1883.
9. Auner HW, Sill H, Mulabecirovic A, Linkesch W, Krause R. Infectious complications after autologous hematopoietic stem cell transplantation: comparison of patients with acute myeloid leukemia, malignant lymphoma, and multiple myeloma. Ann Hematol 2002; 81: 374-377.
10. De Rosa L, Anghel G, Pandolfi A, Riccardi M, Amodeo R, Majolino I. Hemopoietic recovery and infectious complications in breast cancer and multiple myeloma after autologous CD34+ cell-selected peripheral blood progenitor cell transplantation. Int J Hematol 2004; 79: 85-91.
11. Reich G, Mapara MY, Reichardt P, Dorken B, Maschmeyer G. Infectious complications after high-dose chemotherapy and autologous stem cell transplantation: Comparison between patients with lymphoma or multiple myeloma and patients with solid tumors. Bone Marrow Transplant 2001; 27: 525-529.
12. Attal M, Harousseau JL, Stoppa AM, Sotto JJ, Fuzibet JG, Rossi JF, et al. Intergroupe Francais du Myelome. A prospective, randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma. N Engl J Med 1996; 335: 91-97.
13. Jack DL, Klein NJ, Turner MW. Mannose-binding lectin: Targeting the microbial world for complement attack and opsonophagocytosis. Immunol Rev 2001; 180: 86-99.
14. Turner MW, Hamvas RM. Mannose-binding lectin: Structure, function, genetics and disease associations. Rev Immunogenet 2000; 2: 305-322.
15. Petersen SV, Thiel S, Jensenius JC. The mannan-binding lectin pathway of complement activation: Biology and disease association. Mol Immunol 2001; 38: 133-149.
16. Sastry K, Herman GA, Day L, Deignan E, Bruns G, Morton CC et al. The human mannose-binding protein gene. Exon structure reveals its evolutionary relationship to a human pulmonary surfactant gene and localization to chromosome 10 J Exp Med 1989; 170: 1175-1189.
17. Steffensen R, Thiel S, Varming K, Jersild C, Jensenius JC. Detection of structural gene mutations and promoter polymorphisms in the mannan-binding lectin (MBL) gene by polymerase chain reaction with sequence-specific primers. J Immunol Methods 2000; 241: 33-42.
18. Minchinton RM, Dean MM, Clark TR, Heatley S, Mullighan CG. Analysis of the relationship between mannose-binding lectin (MBL) genotype, MBL levels and function in an Australian blood donor population. Scand J Immunol 2002; 56: 630-641.
19. Neth O, Hann I, Turner MW, Klein NJ. Deficiency of mannose-binding lectin and burden of infection in children with malignancy: A prospective study. Lancet 2001; 358: 614-618.
20. Peterslund NA, Koch C, Jensenius JC, Thiel S. Association between deficiency of mannose-binding lectin and severe infections after chemotherapy. Lancet 2001; 358: 637-638.
21. Bergmann OJ, Christiansen M, Laursen I, Bang P, Hansen NE, Ellegaard J et al. Low levels of mannose-binding lectin do not affect occurrence of severe infections or duration of fever in acute myeloid leukaemia during remission induction therapy. Eur J Haematol 2003; 70: 91-97.
22. Kilpatrick DC, McLintock LA, Allan EK, Copland M, Fujita T, Jordanides NE et al. No strong relationship between mannan binding lectin or plasma ficolins and chemotherapy-related infections. Clin Exp Immunol 2003; 134: 279-284.
23. Molle I, Steffensen R, Thiel S, Peterslund NA. Chemotherapy-related infections in patients with multiple myeloma: Associations with mannan-binding lectin genotypes. Eur J Haematol 2006; 77: 19-26.
24. Horiuchi T, Gondo H, Miyagawa H, Otsuka J, Inaba S, Nagafuji K, et al. Association of MBL gene polymorphisms with major bacterial infection in patients treated with high-dose chemotherapy and autologous PBSCT. Genes Immun 2005; 6: 162-166.
25. Cesana C, Nosari AM, Klersy C, Miqueleiz S, Rossi V, Ferrando P et al. Risk factors for the development of bacterial infections in multiple myeloma treated with two different vincristine-adriamycin-dexamethasone schedules. Haematologica 2003; 88: 1022-1028.
26. Steffensen R, Hoffmann K, Varming K. Rapid genotyping of MBL2 gene mutations using real-time PCR with fluorescent hybridisation probes. J Immunol Methods 2003; 278: 191-199.
27. Van Hoeyveld E, Houtmeyers F, Massonet C, Moens L, Van Ranst M, Blanckaert N et al. Detection of single nucleotide polymorphisms in the mannose-binding lectin gene using minor groove binder-DNA probes. J Immunol Methods 2004; 287: 227-230.
28. Oken MM, Creech RH, Tormey DC, Horton J, Davis TE, McFadden ET et al. Toxicity and response criteria of the Eastern Cooperative Oncology Group. Am J Clin Oncol 1982; 5: 649-655.
29. Gordon AC, Waheed U, Hansen TK, Hitman GA, Garrard CS, Turner MW et al. Mannose-binding lectin polymorphisms in severe sepsis: Relationship to levels, incidence, and outcome. Shock 2006; 25: 88-93.